Preferred Label : roflumilast;
MeSH note : inhibits PDE4; structure in first source;
MeSH synonym : 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide;
Is substance : O;
UNII : 0P6C6ZOP5U;
InChIKey : MNDBXUUTURYVHR-UHFFFAOYSA-N;
Origin ID : C424423;
UMLS CUI : C0965618;
ATC code(s)
- ATC code(s)
- Currated CISMeF NLP mapping
- MeSH indexing information
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.ema.europa.eu/medicines/human/EPAR/Daxas
2012
false
United Kingdom
English
French
syndication feed
Product containing precisely roflumilast 500 microgram/1 each conventional release
oral tablet (clinical drug)
Product containing roflumilast (medicinal product)
drug therapy, combination
cyclic nucleotide phosphodiesterases, type 4
roflumilast
roflumilast
roflumilast
drug approval
treatment outcome
aminopyridines
aminopyridines
benzamides
benzamides
cyclopropanes
cyclopropanes
pulmonary disease, chronic obstructive
adult
administration, oral
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
phosphodiesterase 4 inhibitors
phosphodiesterase 4 inhibitors
package leaflet
drug evaluation
summary of product characteristics
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-09/daxas_synthese_09052012.pdf
http://www.has-sante.fr/portail/jcms/c_1263673/daxas-09052012-avis-ct11681
http://www.has-sante.fr/portail/jcms/c_1294100/daxas-roflumilast-inhibiteur-de-la-phosphodiesterase-4
2012
false
France
French
evaluation of the transparency committee
guidelines for drug use
Product containing roflumilast (medicinal product)
Product containing precisely roflumilast 500 microgram/1 each conventional release
oral tablet (clinical drug)
aminopyridines
aminopyridines
benzamides
benzamides
cyclopropanes
cyclopropanes
roflumilast
phosphodiesterase 4 inhibitors
treatment outcome
roflumilast
roflumilast
phosphodiesterase 4 inhibitors
pulmonary disease, chronic obstructive
administration, oral
adult
insurance, health, reimbursement
bronchitis, chronic
drug therapy, combination
disease exacerbation
disease progression
aged
randomized controlled trials as topic
pilot projects
forced expiratory volume
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-06/daxas_09052012_avis_ct11681.pdf
http://www.has-sante.fr/portail/jcms/c_1263603/daxas
2012
false
France
French
evaluation of the transparency committee
Product containing roflumilast (medicinal product)
Product containing precisely roflumilast 500 microgram/1 each conventional release
oral tablet (clinical drug)
roflumilast
roflumilast
administration, oral
insurance, health, reimbursement
pulmonary disease, chronic obstructive
phosphodiesterase 4 inhibitors
phosphodiesterase 4 inhibitors
bronchitis, chronic
adult
drug therapy, combination
roflumilast
aged
treatment outcome
double-blind method
randomized controlled trials as topic
meta-analysis as topic
forced expiratory volume
aminopyridines
aminopyridines
benzamides
benzamides
cyclopropanes
cyclopropanes
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00041
2011
false
Canada
French
English
Product containing precisely roflumilast 500 microgram/1 each conventional release
oral tablet (clinical drug)
Product containing roflumilast (medicinal product)
roflumilast
roflumilast
administration, oral
aminopyridines
aminopyridines
benzamides
benzamides
cyclopropanes
cyclopropanes
phosphodiesterase inhibitors
cyclic nucleotide phosphodiesterases, type 4
pulmonary disease, chronic obstructive
roflumilast
drug approval
treatment outcome
drug evaluation
phosphodiesterase 4 inhibitors
aminopyridines
benzamides
cyclopropanes
drug information
---
https://www.ema.europa.eu/medicines/human/EPAR/Libertek
2011
false
United Kingdom
English
French
syndication feed
Product containing roflumilast (medicinal product)
pulmonary disease, chronic obstructive
adult
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
drug therapy, combination
roflumilast
roflumilast
treatment outcome
drug approval
aminopyridines
aminopyridines
benzamides
benzamides
cyclopropanes
cyclopropanes
roflumilast
administration, oral
cyclic nucleotide phosphodiesterases, type 4
phosphodiesterase 4 inhibitors
phosphodiesterase 4 inhibitors
aminopyridines
benzamides
cyclopropanes
drug evaluation
summary of product characteristics
package leaflet
---
https://www.ema.europa.eu/medicines/human/EPAR/Daliresp
2011
false
United Kingdom
French
English
syndication feed
Product containing roflumilast (medicinal product)
roflumilast
roflumilast
drug approval
treatment outcome
cyclopropanes
cyclopropanes
aminopyridines
aminopyridines
benzamides
benzamides
roflumilast
cyclic nucleotide phosphodiesterases, type 4
administration, oral
pulmonary disease, chronic obstructive
drug therapy, combination
pregnancy
breast feeding
drug interactions
adult
drug evaluation, preclinical
phosphodiesterase 4 inhibitors
phosphodiesterase 4 inhibitors
aminopyridines
benzamides
cyclopropanes
summary of product characteristics
drug evaluation
package leaflet
---
https://www.cadth.ca/sites/default/files/pdf/374_roflumilast_cetap_f.pdf
https://www.cadth.ca/sites/default/files/pdf/374_roflumilast_cetap_e.pdf
2005
Canada
English
French
Asthma chronic
benzamides
treatment outcome
canada
Evidence-Based medicine
bronchodilator agents
clinical trials as topic
double-blind method
asthma
aminopyridines
benzamides
benzamides
cyclic nucleotide phosphodiesterases, type 4
pulmonary disease, chronic obstructive
roflumilast
roflumilast
roflumilast
roflumilast
phosphodiesterase 4 inhibitors
phosphodiesterase 4 inhibitors
aminopyridines
aminopyridines
cyclopropanes
cyclopropanes
cyclopropanes
aminopyridines
benzamides
cyclopropanes
drug evaluation
---
